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of bleeding were present in 6/9 (67%) hypocoagulable and 1/9 (11%) normocoagulable dogs. PT, fibrino-
gen concentration, and several ROTEM parameters were significantly different between hypocoagulable
and normocoagulabe A. vasorum infected dogs. Hyperfibrinolysis was identified in 44% of infected dogs
and was significantly more common in bleeding and hypocoagulable dogs. Hyperfibrinolysis was signifi-
cantly associated with low MCFFib-tem but not with low fibrinogen concentration or increased D-dimers.
CFTEx-tem > 248 swas 100% sensitive and 89% specific to predict hyperfibrinolysis. Hyperfibrinolysis,
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Abstract: Angiostrongylus vasorum infection has been associated with coagulopathies including hyper-
fibrinolysis. We compared coagulation status including thromboelastometry (ROTEM) parameters in
dogs naturally infected with A. vasorum versus healthy dogs to determine clinicopathological param-
eters associated with bleeding, hypocoagulopathy, and hyperfibrinolysis. Clinical signs, white blood
cell count, platelet count, hematocrit, plasmatic coagulation tests (PT, aPTT, fibrinogen concentration),
D-dimer, and ROTEM S parameters (Ex-tem, In-tem, Fib-tem, Ap-tem) were analysed and compared
between bleeding, nonbleeding, and control dogs and between hypo- and normocoagulable animals.
Clinical signs of bleeding were present in 6/9 (67%) hypocoagulable and 1/9 (11%) normocoagulable
dogs. PT, fibrinogen concentration, and several ROTEM parameters were significantly different
between hypocoagulable and normocoagulabe A. vasorum infected dogs. Hyperfibrinolysis was
identified in 44% of infected dogs and was significantly more common in bleeding and hypocoagu-
lable dogs. Hyperfibrinolysis was significantly associated with low MCFFib-tem but not with low
fibrinogen concentration or increased D-dimers. CFTEx-tem > 248 swas 100% sensitive and 89%
specific to predict hyperfibrinolysis. Hyperfibrinolysis, hypocoagulability and bleeding are common
in A. vasorum infected dogs. Only Ex-tem and Fib-tem parameters and potentially PT were associated
with bleeding or hypocoagulability. Ex-tem analysis enables detection of bleeding, hypocoagulability
and hyperfibrinolysis within minutes.
Keywords: angiostrongylosis; bleeding diathesis; fibrinogen
1. Introduction
The canine heart- and lungworm Angiostrongylus vasorum (Baillet 1866) causes serious
infections in dogs and is associated with a high mortality rate if not diagnosed and treated
in due time [1]. The disease often causes a broad spectrum of clinical signs, including
unspecific clinical signs. Bleeding diathesis, present in about 60% of clinical cases, can lead
to rapid life-threatening complications [2] and may occur within the central nervous system,
the lung, body cavities, mucous membranes, or in the integument [3,4]. The mechanisms
and pathogenesis of these coagulopathies are poorly understood and several unresolved
hypotheses such as chronic disseminated intravascular coagulation (DIC), FV and FVIII
deficiency, immune-mediated thrombocytopenia, anticoagulants secreted by the parasite or
activation of the fibrinolytic system of the host have been formulated [2,4–9]. A recent study
evaluating serum proteome of experimentally infected dogs did not support an underlying
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DIC but rather consumption of some key factors of the coagulation and complement
cascade [10]. Interestingly, a previous retrospective study identified hyperfibrinolysis
(HFL) and associated hypofibrinogenemia in 67% of dogs with an A. vasorum infection and
simultaneous clinical signs of bleeding [6]. Hyperfibrinolysis, which can be diagnosed with
rotational thromboelastometry (ROTEM) [11], but not with plasmatic coagulation tests,
may explain the bleeding diathesis seen in some dogs with A. vasorum infection [6].
Eventually, the identification of dogs at risk for bleeding diathesis remains a challenge.
In a previous study, 73% of dogs with A. vasorum infection were hypocoagulable based on
thromboelastography (TEG, which is comparable to ROTEM), with TEG parameters being
significantly different between bleeding and nonbleeding dogs [2]. These authors found no
association between other coagulation parameters (fibrinogen concentration, antithrombin
activity, D-dimers, von Willebrand factor) and hypocoagulable parameters on TEG.
To our knowledge, clinical signs of bleeding, plasmatic coagulation times, true preva-
lence of HFL and its association with bleeding diathesis had not been prospectively evalu-
ated in dogs with A. vasorum infection.
The present study aimed to describe the coagulation status in dogs naturally infected
with A. vasorum, to establish the incidence of HFL and to determine clinicopathological pa-
rameters indicating the presence of HFL by comparing coagulation parameters of infected
dogs to a healthy control group. An additional objective was to evaluate clinicopathological
differences between hypocoagulable and normocoagulable A. vasorum infected dogs.
We hypothesized that dogs naturally infected with A. vasorum and with clinical signs
of bleeding would show changes in coagulation parameters, and that ROTEM parameters
would be superior predictors of HFL than plasmatic coagulation tests or clinical signs
at presentation.
2. Results
Angiostrongylus vasorum positive dogs included five Beagles, three mixed breed dogs
and one each of the following breeds: Belgian Shepherd, Bernese Mountain Dog, Chi-
huahua, Dalmatian, Doberman, German Shepherd, French Bulldog, Golden Retriever,
Hovawart, and Schnauzer. The control group included three mixed breed dogs and one
Beagle, one Belgian Shepherd, one German Pointer, one Golden Retriever, and one Nova
Scotia Duck Tolling Retriever. Breed (p = 0.483), sex (p = 0.230), age (p = 0.154), and weight
(p = 0.441) were not significantly different between dogs with A. vasorum infection and
control dogs.
Of the 18 dogs with A. vasorum infection, 7 presented with clinical or magnetic res-
onance imaging (MRI) signs of bleeding (39%). Bleeding occurred in the brain (n = 3),
episcleral (n = 2), lip (n = 2), lung (n = 1), and nose (n = 1). Three of seven dogs showed
more than one bleeding location. All three dogs with signs of central nervous system (CNS)
bleeding on MRI presented with episcleral bleeding.
Nine of 18 (50%) infected dogs were hypocoagulable. Six of 7 (86%) bleeding dogs and
3/11 (27%) of nonbleeding dogs were hypocoagulable (p = 0.050) while clinical signs of
bleeding were present in 6/9 (67%) hypocoagulable and 1/9 (11%) normocoagulable dogs
(p = 0.050). Hypocoagulable dogs exhibited a median of four different hypocoagulable
parameters (2–7).
Differences between control, infected bleeding and infected nonbleeding dogs are sum-
marized in Tables 1 and 2. None of the evaluated clinical parameters at presentation was
significantly different between groups (Table 1). The group of dogs with bleeding diathe-
sis was thrombocytopenic, had a prolonged prothrombin time (PT) and hypocoagulable
Ex-tem and Fib-tem parameters compared to both nonbleeding and control dogs.
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Table 1. Haematological, plasmatic coagulation, and ROTEM parameters in 8 control dogs and 18 dogs with A. vasorum infection with and without signs of bleeding.
Groups Comparison between Groups
Parameter Reference
Interval
Control (n = 8)
A. vasorum Infected Nonbleeding
(n = 11)










n/N Median Range n/N Median Range n/N Median Range p * P+ P+ P+
Haematological and plasmatic coagulation results
Haematocrit
(%) 42–55 8/8 48 39–51 11/11 42 36–52 6/7 41 32–46 0.064
White blood
cells (10 × 9/L)
4.7–11.3 8/8 7.7 5.1–10.7 11/11 11.7 9.2–21.1 6/7 13.5 10.9–18 0.001 0.003 0.002 1.000
Platelet count
(10 × 9/L)
150–399 7/8 275 213–403 10/11 280 81–421 6/7 130 87–174 0.014 1.000 0.030 0.023
PT (s) 6.5–8.7 8/8 7.2 6.3–7.8 9/11 7.7 7.0–9.9 2/7 17.3 10.5–24.1 0.010 0.126 0.015 0.351
aPTT (s) 10.2–13.8 8/8 11.8 9.6–14.2 9/11 12.1 10.0–15.5 2/7 20.4 14.1–26.7 0.091 NA NA NA
Fibrinogen
Clauss (g/L)
1.2–2.8 8/8 1.9 1–2.3 9/11 1.9 0.7–2.8 3/7 0.9 0.1–1.2 0.052 NA NA NA
D-dimer
(mg/dL)
<0.3 8/8 0.1 0.1–1.7 8/11 0.7 0.1–3.8 2/7 1.4 0.9–1.8 0.123 NA NA NA
ROTEM parameters
CTEx-tem (s) 23–87 8/8 34 25–94 11/11 29 24–113 7/7 138 80–251 0.001 1.000 0.012 0.001
CFTEx-tem (s) 85–357 8/8 188 82–264 11/11 180 53–541 7/7 411 210–3600 0.008 1.000 0.017 0.019
AlphaEx-tem (
◦) 42-77 8/8 58 52–74 11/11 58 35–83 7/7 41 18–53 0.011 1.000 0.019 0.029
MCFEx-tem
(mm) 32-65 8/8 50 41–66 11/11 50 28–72 7/7 29 14-47 0.008 1.000 0.020 0.014
MCEEx-tem 45–142 8/8 100 70–197 11/11 99 38–254 7/7 41 17–89 0.007 1.000 0.019 0.013
MLEx-tem (%) 0–12 8/8 5 1–9 11/11 3 0–11 7/7 32 0-100 0.079 NA NA NA
CTIn-tem (s) 133–210 8/8 160 151–206 10/11 184 149–258 1/7 (289) NA 0.116 NA NA NA
CFTIn-tem (s) 59.201 8/8 102 59–121 10/11 84 51–289 1/7 (294) NA 0.207 NA NA NA
AlphaIn-tem (
◦) 58–78 8/8 71 67–78 10/11 73 47–79 1/7 (48) NA 0.279 NA NA NA
MCFIn-tem (mm) 52–71 8/8 60 57–68 10/11 63 40–72 1/7 (41) NA 0.235 NA NA NA
MCEIn-tem 108–242 8/8 153 130–211 10/11 169 67–260 1/7 (69) NA 0.197 NA NA NA
MLIn-tem (%) 0-3 8/8 1 0–5 10/11 0 0–80 1/7 (0) NA 0.568 NA NA NA
CTFib-tem (s) 21–112 8/8 33 22–464 10/11 36 23–3600 7/7 3600 278–3600 0.002 1.000 0.006 0.005
MCFFib-tem
(mm) 2–9 8/8 4 2–8 11/11 6 0–14 7/7 0 0–2 0.001 1.000 0.028 0.001
MCEFib-tem 2–9 8/8 4 3–9 11/11 7 0–16 7/7 0 0–2 0.001 1.000 0.024 0.001
CTAp-tem (s) 21–75 8/8 29 23–51 9/11 34 24–95 3/7 238 112–265 0.019 1.000 0.016 0.070
CFTAp-tem (s) 99–485 8/8 198 127–371 9/11 162 49–428 3/7 1044 476–3600 0.023 1.000 0.063 0.020
AlphaAp-tem (
◦) 42–79 8/8 66 41–78 9/11 59 43–78 3/7 23 17–36 0.023 1.000 0.021 0.056
MCFAp-tem
(mm)
32–65 8/8 49 37–57 9/11 52 30–70 3/7 26 16–37 0.034 1.000 0.093 0.031
MCEAp-tem 47–175 8/8 98 59–132 7/11 96 43–231 3/7 34 19–59 0.034 0.980 0.085 0.033
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Table 1. Cont.
Groups Comparison between Groups
Parameter Reference
Interval
Control (n = 8)
A. vasorum Infected Nonbleeding
(n = 11)










n/N Median Range n/N Median Range n/N Median Range p * P+ P+ P+




NA 8/8 −14 −22–33 9/11 8 −9–71 3/7 4 −5–14 0.312 NA NA NA
p *, Kruskal–Wallis test; P+, post hoc analysis with Dunn–Bonferroni. aPTT, activated partial thromboplastin time; CT, clotting time; CFT, clot formation time; CT, clotting time; CFT, clot formation time; MCF,
maximum clot firmness; ML, maximum lysis; NA, not assessed; PT, prothrombin time; MCE, maximum clot elasticity; MCF, maximum clot firmness; ML, maximum lysis; PT, prothrombin time.
Table 2. Respiratory clinical and radiographic signs, haematological and ROTEM abnormalities and treatment in 8 control, 11 infected nonbleeding, and 7 infected bleeding dogs with A.
vasorum infection.
Groups Comparison between Groups *
Parameter Control (n = 8)
A. vasorum Infected
Nonbleeding (n = 11)
A. vasorum Infected








n/N (%) n/N (%) n/N (%) p p p p
Respiratory clinical and radiographic signs indicative for canine angiostrongylosis
Cough 0/8 5/11 (46%) 2/7 (28%) 0.063 NA NA NA
Respiratory distress 0/8 2/11 (18%) 1/7 (14%) 1.000 NA NA NA
Interstitial pattern on
chest radiographs
NA 4/6 (67%) 4/4 (100%) 0.467 NA NA NA
Abnormal haematological and plasmatic coagulation parameters
Thrombocytopenia
(<150 × 109/L)
1/8 (13%) 1/10 (10%) 5/6 (83%) 0.004 1.000 0.026 0.008
PT > 8.7 s 0/8 2/9 (22%) 2/2 (100%) 0.017 0.471 0.022 0.109
aPTT > 13.8 s 1/8 (13%) 1/9 (11%) 2/2 (100%) 0.053 1.000 0.067 0.055
Fibrinogen Clauss <1.2 g/L 0/8 1/9 (11%) 2/3 (67%) 0.046 1.000 0.055 0.127
D-dimers > 0.3 mg/dL 2/8 (25%) 4/8 (50%) 2/2 (100%) 0.171 0.608 0.133 0.467
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Table 2. Cont.
Groups Comparison between Groups *
Parameter Control (n = 8)
A. vasorum Infected
Nonbleeding (n = 11)
A. vasorum Infected








n/N (%) n/N (%) n/N (%) p p p p
Hypocoagulable ROTEM parameters
CTEx-tem > 87 s 1/8 (13%) 1/11 (9%) 6/7 (86%) 0.001 1.000 0.010 0.002
CFTEx-tem > 328 s 0/8 3/11 (27%) 6/7 (86%) 0.002 0.228 0.001 0.050
AlphaEx-tem < 42
◦ 0/8 1/11 (9%) 4/7 (57%) 0.011 1.000 0.026 0.047
MCFEx-tem < 32 mm 0/8 1/11 (9%) 5/7 (71%) 0.002 1.000 0.007 0.013
MCEEx-tem < 45 0/8 1/11 ()%) 5/7 (71%) 0.002 1.000 0.007 0.013
MLEx-tem > 12% 0/8 0/11 4/7 (57%) 0.002 NA 0.026 0.011
CTIn-tem > 211 s 0/8 3/10 (30%) 1/1 (100%) 0.063 0.216 0.111 0.364
CFTIn-tem > 130 s 0/8 2/10 (20%) 1/1 (100%) 0.075 0.477 0.111 0.273
AlphaIn-tem > 58
◦ 0/8 1/10 (10%) 1/1 (100%) 0.105 1.000 0.111 0.182
MCFIn-tem < 57 mm 0/8 2/10 (20%) 1/1 (100%) 0.075 0.477 0.111 0.273
MCEIn-tem < 108 0/8 2/10 (20%) 1/1 (100%) 0.075 0.477 0.111 0.273
MLIn-tem > 5% 0/8 2/10 (20%) 0/1 0.532 0.477 NA 1.000
CTFib-tem > 112 s 3/8 (38%) 1/10 (10%) 7/7 (100%) 0.001 0.275 0.026 <0.001
MCFFib-tem 0 mm 0/8 1/11 (9%) 6/7 (86%) <0.001 1.000 0.001 0.002
MCFAp-tem > MCFEx-tem 2/8 (25%) 2/9 (18%) 0/3 1.000 1.000 1.000 1.000
Treatment
Plasma transfusion NA 0/11 4/7 (57%) NA NA NA 0.011
Tranexamic acid NA 0/11 5/7 (71%) NA NA NA 0.002
* chi2 test; aPTT, activated partial thromboplastin time; CT, clotting time; CFT, clot formation time; AUC, area under the curve; CI, confidence interval; CT, clotting time; CFT, clot formation time; MCF, maximum
clot firmness; ML, maximum lysis; PT, prothrombin time; MCE, maximum clot elasticity; MCF, maximum clot firmness; ML, maximum lysis; NA, not assessed; PT, prothrombin time.
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Differences between hypocoagulable and normocoagulable A. vasorum infected dogs
are summarized in Tables 3 and 4. None of the clinical signs occurred in different frequency
between hypo- and normocoagulable dogs. Platelet count (but not the presence of throm-
bocytopenia), PT, and several ROTEM parameters were significantly different between
hypocoagulable and normocoagulabe A. vasorum infected dogs. Clinical signs and the
localization of clinical manifestations were not significantly different between hypo- and
normocoagulable dogs.
Table 3. Differences in haematological, plasmatic coagulation and ROTEM parameters between hypo- vs. normocoagulable
A. vasorum infected dogs.
Parameter Normocoagulable (n = 9) Hypocoagulable (n = 9)
n/N Median Range n/N Median Range Reference Interval p *
Haematological and plasmatic coagulation parameters
Haematocrit (%) 9/9 44 32–52 9/9 41 36–46 42–55 0.423
White blood cells (109/L) 9/9 11.7 9.2–15.2 8/9 13.7 10.9–21.1 4.7–11.3 0.139
Platelet count (109/L) 8/9 292 137–421 8/9 136 81–286 150–399 0.007
PT (s) 6/9 7.6 7.0–8.5 5/9 9.9 7.7–24.1 6.5–8.7 0.017
aPTT (s) 6/9 12.1 10.0–12.6 5/9 14.1 11.6–26.7 10.2 –13.8 0.082
Fibrinogen Clauss (g/L) 7/9 1.9 1.2–2.8 5/9 0.9 0.1–2.3 1.2–2.8 0.073
D-dimer (mg/dL) 6/9 0.7 0.1–3.8 4/9 0.9 0.5–1.8 <0.3 1.000
ROTEM parameters
CTEx-tem (s) 9/9 29 24–80 9/9 134 27–251 23–87 0.001
CFTEx-tem (s) 9/9 175 53–359 9/9 411 180–3600 85–357 0.001
AlphaEx-tem (
◦) 9/9 58 47–83 9/9 41 18–58 42–77 0.003
MCFEx-tem (mm) 9/9 50 35–72 9/9 29 14–54 32–65 0.002
MCEEx-tem 9/9 99 53–254 9/9 41 17–117 45–142 0.002
MLEx-tem (%) 9/9 2 0–4 9/9 11 0–100 0–12 0.063
CtIn-tem (s) 7/9 173 149–233 4/9 226 168–289 133–210 0.230
CFTIn-tem (s) 7/9 83 51–105 4/9 255 79–294 59–201 0.073
AlphaIn-tem (
◦) 7/9 73 69–79 4/9 56 47–74 58–78 0.073
MCFIn-tem (mm) 7/9 63 62–72 4/9 44 40–64 52–71 0.073
MCEIn-tem 7/9 172 164–260 4/9 79 67–177 108–242 0.073
MLIn-tem (%) 7/9 0 0–22 4/9 1 0–80 0–3 0.412
CTFib-tem (s) 8/9 36 25–278 9/9 3600 23–3600 21–112 0.008
MCFFib-tem (mm) 9/9 6 2–14 9/9 0 0–5 2–9 <0.001
MCEFib-tem 9/9 7 2–16 9/9 0 0–5 2–9 <0.001
CTAp-tem (s) 6/9 32 24–45 6/9 104 26–265 21–75 0.041
CFTAp-tem (s) 6/9 125 59–193 6/9 452 238–3600 99–485 0.002
AlphaAp-tem (
◦) 6/9 67 55–78 6/9 40 17–52 42–79 0.002
MCFAp-tem (mm) 6/9 57 49–70 6/9 34 16–49 32–65 0.002
MCEAp-tem 4/9 152 94–231 6/9 51 19–96 47–175 0.019
MLAp-tem (%) 6/9 1 0–2 6/9 0 0–100 0–10 0.818
Delta
MCFAp-tem-MCFEx-tem (%)
6/9 9.5 1.7–71.4 6/9 5.6 −9.3–14.3 0.240
* p determined by Mann–Whitney U-test; aPTT, activated partial thromboplastin time; CT, clotting time; CFT, clot formation time; CT,
clotting time; CFT, clot formation time; MCF, maximum clot firmness; ML, maximum lysis; PT, prothrombin time; MCE, maximum clot
elasticity; MCF, maximum clot firmness; ML, maximum lysis; PT, prothrombin time.
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Table 4. Comparison of the occurrence of clinicopathological variables between normo- and hypocoagulable A. vasorum
infected dogs.
Parameter Normocoagulable (n = 9) Hypocoagulable (n = 9)
n/N (%) n/N (%) p
Localization of clinical manifestation
Mucocutaneous bleeding 1/9 (11%) 2/9 (22%)
0.086
Lung 4/9 (44%) 2/9 (22%)
CNS 0 4/9 (44%)
Incidental diagnosis 4/9 (44%) 1/9 (11%)
Respiratory clinical and radiographic signs and bleeding indicative for canine angiostrongylosis
Cough 4/9 (44%) 2/9 (22%) 0.620
Respiratory distress 1/9 (11%) 2/9 (22%) 0.500
Alveolar-interstitial pattern on chest radiographs 4/5 (80%) 4/5 (80%) 1.000
Clinical signs of bleeding 1/9 (11%) 6/9 (67%) 0.050
Hematological parameters correlated with coagulation
Thrombocytopenia 1/8 (13%) 5/8 (63%) 0.119
PT > 8.7 s 0/6 4/5 (80%) 0.015
aPTT > 13.8 s 0/6 3/5 (60%) 0.061
Fibrinogen Clauss < 1.2 g/L 0/7 3/5 (60%) 0.045
D-dimer > 0.3 mg/dL 3/6 (50%) 3/4 (75%) 0.571
ROTEM parameters
CTEx-tem > 87 s 0/9 7/9 (78%) 0.002
CFTEx-tem > 328 s 1/9 (11%) 8/9 (89%) 0.003
MCFEx-tem < 32 mm 0/9 6/9 (67%) 0.009
alphaEx-tem < 42
◦ 0/9 5/9 (56%) 0.029
MCEEx-tem < 45 0/9 6/9 (67%) 0.009
MLEx-tem > 12% 0/9 4/9 (44%) 0.082
CTIn-tem > 211 s 2/7 (29%) 2/4 (50%) 0.576
CFTIn-tem > 130 s 0/7 3/4 (75%) 0.024
MCFIn-tem < 57 mm 0/7 3/4 (75%) 0.024
alphaIn-tem > 58
◦ 0/7 2/4 (50%) 0.109
MLIn-tem > 5% 1/7 (14%) 1/4 (25%) 1.000
MCEIn-tem < 108 0/7 3/4 (75%) 0.024
CTFib-tem > 112 s 1/8 (13%) 7/9 (78%) 0.015
MCFFib-tem 0 mm 0/9 7/9 (78%) 0.002
Treatment
Plasma transfusion 0/9 4/9 (44%) 0.082
Tranexamic acid 0/9 5/9 (56%) 0.029
aPTT, activated partial thromboplastin time; CT, clotting time; CFT, clot formation time; AUC, area under the curve; CI, confidence interval;
CT, clotting time; CFT, clot formation time; MCF, maximum clot firmness; ML, maximum lysis; PT, prothrombin time; MCE, maximum clot
elasticity; MCF, maximum clot firmness; ML, maximum lysis; PT, prothrombin time.
Overall incidence of HFL defined by maximum lysis above the reference interval in
any of the ROTEM tracings was 44% in dogs with A. vasorum infection (8/18 dogs) and was
significantly higher in bleeding dogs (p = 0.011; Table 2) and hypocoagulable dogs (p = 0.015,
Table 4). Four of 7 (57%) bleeding dogs showed increased Ex-tem lysis compared to none
of the nonbleeding dogs (p = 0.011). Hyperfibrinolysis was significantly associated with
low MCFFib-tem (p = 0.001) but not with low fibrinogen concentration (p = 0.088). AUROC
results for prediction of HFL are shown in Table 5. CFTEx-tem > 248 s was 100% sensitive
and 89% specific and CTExtem > 103 s was 75% sensitive and 99% specific. Hyperfibrinolysis
was not associated with high D-dimers (p = 0.559).
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Table 5. AUROC analysis for specific factors to predict hyperfibrinolysis in 18 dogs with A. vasorum infection.
Parameter AUC 95% CI p
CTEx-tem 0.781 0.552–1.000 0.024
CFTEx-tem 0.951 0.874–1.000 <0.001
PT 0.808 0.593–1.000 0.064
Fibrinogen Clauss 0.336 0.000–0.702 0.321
MCFEx-tem 0.042 0.000–0.115 <0.001
MLEx-tem 0.125 0.000–0.273 0.003
Platelet count 0.250 0.050–0.450 0.072
AUC, area under the curve; CI, confidence interval; CT, clotting time; CFT, clot formation time; MCF, maximum clot firmness; ML,
maximum lysis; PT, prothrombin time.
All dogs were discharged from the hospital. Four dogs had been treated with fresh
frozen plasma (20–30 mL/kg BW) and additionally received tranexamic acid (20–60 mg/kg).
These four dogs were bleeding, hypocoagulable, and lacked clot formation in the Fib-tem
tracing. An additional bleeding dog was treated with tranexamic acid. Plasma transfu-
sion was significantly associated with low fibrinogen Clauss (p = 0.045), low MCFFib-tem
(p = 0.011), CTEx-tem prolongation (p = 0.011), and bleeding (p = 0.011) but not with hypoco-
agulability (p = 0.082).
Ap-tem tracings showed both weaker and stronger MCFs than Ex-tem profiles.
MCFAp-tem was not stronger (indicating HFL) in any of the 5 dogs with HFL diagnosed in
Ex-tem or In-tem but was > 15% stronger in 4/15 dogs with no HFL and ML’s within the
reference interval.
3. Discussion
The present prospective study identified bleeding diathesis in 39% of dogs naturally
infected with A. vasorum. Among those, 86% were diagnosed hypocoagulable by throm-
boelastometry and plasmatic coagulation tests. Hyperfibrinolysis was present in 44% of all
infected dogs and in 56% of those dogs with bleeding diathesis.
The true incidence of A. vasorum associated bleeding diathesis remains unknown, as
this study was based mostly on referred cases. However, our incidence of 39% is in the
range of previously reported incidences between 35% and 57% [6,12].
The main clinical signs of dogs naturally infected with A. vasorum are coughing
and tachypnea/dyspnea together with unspecific signs such as lethargy, anorexia, and
vomiting/diarrhea [2,4,12–15]. Haemorrhage and neurological signs are less frequently
observed [4,12]. None of the clinically evaluated parameters in the current study were
significantly associated with the presence of haemorrhage, as previously observed [2].
ROTEM analysis identified several parameters that were significantly different be-
tween dogs with bleeding diathesis compared to infected dogs without bleeding and
healthy control dogs. Prolonged CTEx-TEM, CFTEx-TEM, decreased MCFEx-tem and MCFFib-tem,
and Ex-TEM HFL were significantly associated with the presence of bleeding. These find-
ings indicate that both clot formation and clot strength are affected in dogs with A. vasorum
induced coagulopathy.
In contrast to a previous report [2], our study population of dogs with bleeding
diathesis showed a significantly lower median platelet count compared to both nonbleeding
dogs and healthy control dogs. The platelet count of bleeding dogs was below the reference
interval but not in a range that would explain spontaneous bleeding. Several studies
and case reports demonstrated thrombocytopenia and prolonged clotting times [8,16–18],
but experimental studies indicate that such findings are inconsistent over time [7,9,13].
Thrombocytopenia was significantly associated with the presence of bleeding in our study
population and 83% of dogs with bleeding were thrombocytopenic (n = 5/6), while this
was observed in only 10% (n = 1/10) of nonbleeding infected dogs. However, no reasonable
platelet count cut-off value to identify dogs with bleeding diathesis could be identified
and whether the decreased platelet count is the cause or the result of bleeding is unknown.
Together with the identified mild thrombocytopenia, we interpret this finding as evidence
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that thrombocytopenia is a consequence rather than the cause of bleeding, indicating that
mechanisms other than thrombocytopenia are causing bleeding diathesis.
The PT, aPTT, and fibrinogen concentration were not significantly associated with
bleeding, indicating that viscoelastic testing is superior to classical plasmatic coagulation
times for the identification of bleeding in A. vasorum infected dogs.
While overt clinical signs of bleeding will guide the clinician to investigate the co-
agulation status, internal bleeding in the brain or lung may be fatal if hypocoagulability
is not detected and treated [17,19]. The recognition of dogs at risk for bleeding diathesis
remains a challenge [6]. Therefore, the identification of valid prediction parameters to
detect hypocoagulability are of relevant clinical interest.
We therefore analysed clinical and laboratory parameters to detect hypocoagulability
in A. vasorum infected dogs. Of interest, only two-thirds of hypocoagulable dogs showed
clinical signs of bleeding and more than one-quarter of nonbleeding dogs were hypocoag-
ulable and hence at risk to develop bleeding during hospitalization. Cough, pulmonary
changes consistent with radiographic signs of A. vasorum infection [20] on radiographs and
presence of respiratory signs were not associated with hypocoagulability, suggesting that
respiratory signs and the typical interstitial-alveolar pattern seen on thoracic radiographs
are not caused by haemorrhage; consequently, thoracic radiographs will not aid in the
identification of hypocoagulable dogs. This finding is supported by a study evaluating
radiographic, CT and necropsy findings in experimentally infected dogs and linking them
to granulomatous inflammation rather than haemorrhage [20].
Of note, all dogs with neurological signs were hypocoagulable. Such A. vasorum
infected dogs commonly do not present with classical pulmonary signs and internal
haemorrhage may not be apparent [17]. However, the three dogs with neurological signs
all presented with episcleral bleeding, a finding that should be investigated in a larger
study population. Until then, it is important to not only include A. vasorum infection
as a differential diagnosis to central nervous clinical signs but to further investigate the
coagulation status for hypocoagulability if the dogs are infected.
In contrast, none of the dogs with an incidental diagnosis of A. vasorum infection
was hypocoagulable. We suspect that these dogs were either not infected long enough
to develop coagulopathies or with too few worms to show hypocoagulability or clinical
signs of bleeding. Experimentally inoculated dogs with higher worm burdens showed
earlier and more severe respiratory signs and more pronounced coagulopathies [13]. The
magnitude of parasite burden was unknown in our study population; therefore, a direct
comparison cannot be made. In addition, individual differences between dogs cannot be
excluded: the study of dog serum proteome in experimentally infected dogs revealed that
the lectin pathway and the coagulation cascades were particularly affected; these may be
additionally associated with individual differences that altogether may explain the onset
or absence of hypocoagulability [10].
In the present work, not all hypocoagulable dogs exhibited identifiable signs of
bleeding, highlighting the need for laboratory analysis of coagulation status to identify
dogs at risk of bleeding. Hypocoagulable dogs had significantly longer PT and abnormal
Ex-tem, In-tem, and Fib-tem parameters but no significant thrombocytopenia or prolonged
aPTT. Previously, no associations could be identified between coagulation parameters
(fibrinogen concentration, antithrombin activity, D-dimers, von Willebrand factor) and
hypocoagulable thromboelastography parameters [2], indicating that viscoelastic tests may
be more appropriate to identify hypocoagulable dogs.
We recently retrospectively identified HFL and associated hypofibrinogenemia in A.
vasorum infected dogs [6], two findings that are supported by the data presented here.
Hyperfibrinolysis was identified in 44% of dogs naturally infected with A. vasorum and
5/9 (56%) of bleeding dogs showed increased Ex-tem or In-tem lysis compared to 1/9
(11%) nonbleeding dogs. Both bleeding and hypocoagulable dogs had low to no fibrin
clot formation compared to nonbleeding dogs. Hypofibrinogenemia was significantly
more common in hypocoagulable dogs. Bleeding dogs displaying decreased fibrinogen
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concentration have also been described previously [2]. As suggested earlier [5,6], the cause
of decreased fibrin clot formation in the Fib-tem tracing may be explained by HFL and
not by low fibrinogen concentrations. Hyperfibrinolysis was significantly associated with
MCFFib-TEM but not with fibrinogen concentration measured by Clauss. Identification
and treatment of HFL therefore seems to be of clinical relevance. Neither platelet count
nor plasmatic coagulation times are able to predict or diagnose HFL. ROTEM analysis;
however, was able to predict HFL by means of prolonged CT and CFT within minutes.
The initial study protocol envisaged Ap-tem profiles to confirm HFL identified in
Ex-tem profiles. Our study, showing inconsistent Ap-tem results, supports earlier evidence
that Ap-tem assays are not helpful in the diagnosis of HFL in dogs [6,11].
Elevated D-dimer concentrations in dogs with A. vasorum infection have also been
described [2,17,21]. Although expected to increase with fibrinolysis, D-dimer levels were
not different between hypo- and normocoagulable dogs in our study population and
were not associated with HFL. A reason for this finding may be that the presence of D-
dimers requires lysis of crosslinked fibrin while A. vasorum associated lysis of fibrinogen
or fibrin strands may occur prior to crosslinking to a stable fibrin clot [6]. Fibrinogen,
being an acute phase protein, is expected to be present at high levels in dogs with A.
vasorum infections. Another possible explanation for the lack of stable fibrinogen clot is
FXIII deficiency or malfunction. FXIII is needed for cross-linking of fibrin and congenital
or acquired deficiency leads to unexpected bleeding in people [22,23]. In line with this,
a recent time-course proteomics study performed on sera of A. vasorum infected dogs
identified FXIII-B, a subunit of FXIII, as downregulated among other candidates of the
coagulation cascade and complement pathway compared to before inoculation with the
parasite [10].
While significantly more hypocoagulable dogs were treated with tranexamic acid,
hypocoagulability was not significantly associated with administration of a plasma trans-
fusion. Significantly more plasma transfusions were given to bleeding dogs, however, a
plasma transfusion was not deemed necessary in 3/7 dogs with bleeding, based on coagu-
lation parameters. Together with the wide variety of identified ROTEM abnormalities in
hypocoagulable dogs, this indicates that coagulation testing the complete set of coagulation
parameters is crucial to identify not only dogs at risk for bleeding but also to treat the
coagulation disorder with specific therapeutic measures.
In former studies up to 30% of A. vasorum infected dogs died [2,12], while all dogs
in this study were discharged from the hospital. It is possible that early identification of
coagulation problems and early therapeutic intervention has led to the excellent survival
rate in our study population. As all patients were treated based on ROTEM results as well
as at the discretion of the clinician in charge, the effect of treatment on survival cannot be
investigated further.
This study included only a small group of A. vasorum infected dogs and only part of
them showed bleeding diathesis. Unfortunately, bleeding dogs were often presented dur-
ing emergency hours when plasmatic coagulation testing was not available. We however
showed that results of plasmatic coagulation testing should be interpreted with caution.
Additionally, when ROTEM tests were chosen by the clinician in charge during emergency
service hours, in several patients In-tem analysis was not performed. In-tem parameters be-
tween bleeding and nonbleeding A. vasorum infected dogs could therefore not be compared.
Bleeding was furthermore based on visible clinical signs of bleeding and MRI, with the
possibility of having falsely assigned an internally bleeding dog to the nonbleeding group.
4. Materials and Methods
Dogs presenting to the Small Animal Clinic, Vetsuisse Faculty, University of Zurich
between March 2016 and July 2019 and being diagnosed with A. vasorum infection by
either serological ELISA antigen or rapid-assay (AngioDetectTM) [24,25] and/or copromi-
croscopic identification of first stage larvae by the Baermann funnel method were eligible
to enter this and a concurrent study. Healthy dogs were used as a control group. Control
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dogs had a normal complete blood cell and chemistry panel, plasmatic coagulation times
including fibrinogen measured by Clauss and were negative for A. vasorum infection. The
project was approved by the ethics committee on animal research of the canton of Zurich
(ZH001/16,27384) and informed owner consent was obtained for both healthy and infected
dogs, in which additional blood tests were performed for the study.
Dogs were excluded if they were pre-treated with antifibrinolytics, blood products
or NSAIDS within five days of presentation and if ROTEM analysis was not performed
within 30 min after blood sampling.
Signalment, sex, weight, presenting complaint, clinical signs including the presence of
bleeding were determined at presentation. The infected dogs were assigned to the bleeding
or the nonbleeding group based on the presence of clinical signs of bleeding or MRI signs
compatible with bleeding in dogs undergoing MRI exam. In addition, clinical signs were
categorized as mucocutaneous bleeding, lung or CNS localization or incidental diagnosis
without clinical signs (localization of clinical manifestation). Diagnostic imaging findings
and survival to discharge were extracted later from patient records.
Approximately 8–12 mL of venous blood were drawn at presentation or immediately
after diagnosis of A. vasorum infection using a 20 G hypodermic needle. Blood samples
were transferred to tubes in the following order: two 3.2% citrate and one EDTA tube
(all Sarstedt AG, Sevelen, Switzerland). One citrate and the EDTA tube were sent to the
in-house laboratory for plasmatic coagulation tests (PT, aPTT, TT, fibrinogenClauss, and
D-dimers) (Start 4 STAGO CH SA, Glattbrugg, Switzerland) and complete blood cell status
(Sysmex-XT 2000iV, Sysmex Cooperation, Kobe, Japan). Another citrate tube was placed
within the warming plate of the ROTEM device for 10–20 min.
Ex-tem S, In-tem S, Fib-tem S, and Ap-tem S analysis (TEM International GmbH,
Munich) were performed by the primary investigators according to an institutional protocol
based on the manufacturer’s instruction and international guidelines [26,27]. Briefly, 300 µL
citrated whole blood were incubated with the lyophilized reagent before placement in
the cup and start of measurement. An automated pipetting system was used. Tracings
were run for 60 min. All tracings were checked for artefacts by two of the authors (N.E.S,
A.P.N.K). Clotting time (CT), clot formation time (CFT), alpha angle (a), maximum clot
firmness (MCF), maximum clot elasticity (MCE) and maximum lysis (ML) were extracted
from the ROTEM database. A green line in the fib-tem tracing was defined as an MCFFib-tem
of 0 mm. If MCF did not reach 20 mm, CFT was defined as 3600 s. Hypofibrinogenemia
was defined as fibrinogen measured by Clauss < 1.2 g/L (in-house reference interval) or
MCFFib-tem < 2 mm.
Based on ROTEM profiles, dogs were categorized as hypocoagulable if ≥2 of the
following parameters were hypocoagulable compared to reference intervals [28]: CTEx-tem
or PT, CTIn-tem or aPTT, CFTEx-tem / In-tem or α Ex-tem / In-tem, MCFEx-tem / In-tem / Fib-tem or
MCEEx-tem / In-tem / Fib-tem. Hyperfibrinolysis was defined as ML > reference interval in any
of the tracings. Dogs were treated at the discretion of the clinician in charge, generally based
on a standardized protocol including 50 mg/kg BW fenbendazole daily for three weeks and
1 mg/kg BW prednisolone daily for seven days was administered; strict exercise constraint
was advised. Fresh frozen plasma (20 mL/kg BW) was transfused for hypofibrinogenemia
and tranexamic acid was prescribed to treat HFL (20 mg/kg BW, repeated until HFL
resolved) as needed.
Statistical Analysis
Data were entered into a spreadsheet and analyses were performed using the statistical
software program IBM SPSS (Version 23.0. IBM Corp, Armonk, NY, USA). Continuous
data is presented as median (min-max). Clinical signs and coagulation parameters were
compared between dogs with and without bleeding diathesis and control dogs using
Kruskal–Wallis tests followed by post hoc analysis with Dunn-Bonferroni for continuous
variables and chi2 test for categorical variables. In a second step dogs with A. vasorum
infection were grouped as hypo- or normocoagulable and clinical signs and coagulation
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parameters were compared across groups using Mann–Whitney U-test or Fisher’s exact
test. The accuracy of standard coagulation tests and ROTEM parameters to determine dogs
with HFL was evaluated using receiver operating characteristics (ROC) and the area under
the ROC curve (AUROC). Youden’s J statistic was used to select the optimum cut-off point
of the ROC curves. A value of p < 0.05 was considered significant.
5. Conclusions
In conclusion, HFL, hypocoagulability and bleeding are commonly occurring in
A. vasorum infected dogs. None of the evaluated clinical parameters are significantly
associated with bleeding or hypocoagulability, and plasmatic coagulation tests did not
allow clear discrimination between bleeding and nonbleeding A. vasorum infected dogs. In
contrast, most ROTEM parameters were significantly different between groups, allowing
the differentiation between bleeding and nonbleeding A. vasorum infected dogs. Ex-tem
analysis was able to detect bleeding, hypocoagulability, and HFL within a few minutes
after blood draw and may therefore be recommended.
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